BioCentury
ARTICLE | Company News

Novartis exercises option for Conatus NASH candidate emricasan

May 5, 2017 1:37 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option for exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) under a December 2016 deal. Conatus will receive a $7 million option exercise payment (see BioCentury, Dec. 28, 2016)...

BCIQ Target Profiles

Caspases